Figure S8 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

Bomiao Hu; Marc Wiesehöfer; Fernando J. de Miguel; Zongzhi Liu; Lok-Hei Chan; Jungmin Choi; Mary Ann Melnick; Anna Arnal Estape; Zenta Walther; Dejian Zhao; Francesc López‐Giráldez; Anna Wurtz; Guoping Cai; Rong Fan; Scott Gettinger; Andrew Xiao; Qin Yan; Robert Homer; Don X. Nguyen; Katerina Politi

doi:10.1158/0008-5472.25785266.v1

Abstract

Changes in chromatin accessibility in HCC827 and PC9 cells upon ASCL1 expression. Global changes in chromatin accessibility in mutant EGFR lung cancer cell lines following ASCL1 overexpression and osimertinib treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hu et al. (2024) studied this question.

synapsesocial.com/papers/68e6aeb0b6db64358763076d https://doi.org/10.1158/0008-5472.25785266.v1

View Full Paper

Ask AI

Bookmark

Share

Figure S8 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

Abstract

Discussion

Cite This Study

Figure S8 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

Abstract

Discussion

Cite This Study

Keep reading

Keep reading